- Home
- EVM vs TVRD Comparison
EVM vs TVRD Comparison
Compare EVM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- TVRD
- Stock Information
- Founded
- EVM 2002
- TVRD 2017
- Country
- EVM United States
- TVRD United States
- Employees
- EVM N/A
- TVRD N/A
- Industry
- EVM Finance/Investors Services
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- TVRD Health Care
- Exchange
- EVM Nasdaq
- TVRD Nasdaq
- Market Cap
- EVM 213.2M
- TVRD 246.5M
- IPO Year
- EVM N/A
- TVRD N/A
- Fundamental
- Price
- EVM $9.00
- TVRD $29.58
- Analyst Decision
- EVM
- TVRD Strong Buy
- Analyst Count
- EVM 0
- TVRD 5
- Target Price
- EVM N/A
- TVRD $59.20
- AVG Volume (30 Days)
- EVM 55.8K
- TVRD 21.4K
- Earning Date
- EVM 01-01-0001
- TVRD 08-14-2025
- Dividend Yield
- EVM 4.01%
- TVRD N/A
- EPS Growth
- EVM N/A
- TVRD N/A
- EPS
- EVM 0.20
- TVRD N/A
- Revenue
- EVM N/A
- TVRD N/A
- Revenue This Year
- EVM N/A
- TVRD N/A
- Revenue Next Year
- EVM N/A
- TVRD N/A
- P/E Ratio
- EVM $47.61
- TVRD N/A
- Revenue Growth
- EVM N/A
- TVRD N/A
- 52 Week Low
- EVM $7.67
- TVRD $8.13
- 52 Week High
- EVM $9.59
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- EVM 56.97
- TVRD 63.37
- Support Level
- EVM $8.87
- TVRD $22.91
- Resistance Level
- EVM $9.14
- TVRD $31.54
- Average True Range (ATR)
- EVM 0.08
- TVRD 1.61
- MACD
- EVM 0.01
- TVRD 0.51
- Stochastic Oscillator
- EVM 57.14
- TVRD 77.33
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.